These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 39267958)

  • 41. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S; Sucić AF; Martinac AI
    Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Regulatory registration timelines of generic medicines in South Africa: Assessment of the performance of SAHPRA between 2011 and 2022.
    Moeti L; Litedu M; Joubert J
    J Pharm Policy Pract; 2023 Mar; 16(1):34. PubMed ID: 36864490
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 45. South African Regulatory Authority: The Impact of Reliance on the Review Process Leading to Improved Patient Access.
    Keyter A; Salek S; Danks L; Nkambule P; Semete-Makokotlela B; Walker S
    Front Pharmacol; 2021; 12():699063. PubMed ID: 34366850
    [No Abstract]   [Full Text] [Related]  

  • 46. Accelerating access to new medicines: Current status of facilitated regulatory pathways used by emerging regulatory authorities.
    Liberti L; Breckenridge A; Hoekman J; Leufkens H; Lumpkin M; McAuslane N; Stolk P; Zhi K; Rägo L
    J Public Health Policy; 2016 Aug; 37(3):315-333. PubMed ID: 26961261
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Can Standardisation of the Public Assessment Report Improve Benefit-Risk Communication?
    Keyter A; Salek S; Banoo S; Walker S
    Front Pharmacol; 2020; 11():855. PubMed ID: 32625087
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expanding global access to essential medicines: investment priorities for sustainably strengthening medical product regulatory systems.
    Roth L; Bempong D; Babigumira JB; Banoo S; Cooke E; Jeffreys D; Kasonde L; Leufkens HGM; Lim JCW; Lumpkin M; Mahlangu G; Peeling RW; Rees H; Ndomondo-Sigonda M; Stergachis A; Ward M; Nwokike J
    Global Health; 2018 Nov; 14(1):102. PubMed ID: 30382856
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current global status of male reproductive health.
    De Jonge CJ; Barratt CLR; Aitken RJ; Anderson RA; Baker P; Chan DYL; Connolly MP; Eisenberg ML; Garrido N; Jørgensen N; Kimmins S; Krausz C; McLachlan RI; Niederberger C; O'Bryan MK; Pacey A; Priskorn L; Rautakallio-Hokkanen S; Serour G; Veltman JA; Vogel DL; Vazquez-Levin MH
    Hum Reprod Open; 2024; 2024(2):hoae017. PubMed ID: 38699533
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative Assessment of the National Pharmacovigilance Systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania.
    Barry A; Olsson S; Minzi O; Bienvenu E; Makonnen E; Kamuhabwa A; Oluka M; Guantai A; Bergman U; van Puijenbroek E; Gurumurthy P; Aklillu E
    Drug Saf; 2020 Apr; 43(4):339-350. PubMed ID: 31919794
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Medicines Regulation in Africa: Current State and Opportunities.
    Ndomondo-Sigonda M; Miot J; Naidoo S; Dodoo A; Kaale E
    Pharmaceut Med; 2017; 31(6):383-397. PubMed ID: 29200865
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Actions of the National Regulatory Authorities in 10 Low- and Middle-Income Countries Following Stringent Regulatory Authority Safety Alerts on Rosiglitazone.
    Nwokike J; Kabore L; Stergachis A
    Ther Innov Regul Sci; 2015 Mar; 49(2):279-283. PubMed ID: 30222412
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of the Performance of the South Africa Regulatory Agency: Recommendations for Improved Patients' Access to Medicines.
    Keyter A; Salek S; Gouws J; Banoo S; Walker S
    Ther Innov Regul Sci; 2020 Jul; 54(4):878-887. PubMed ID: 32557310
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Implementation and performance of haemovigilance systems in 10 sub-saharan African countries is sub-optimal.
    Samukange WT; Kluempers V; Porwal M; Mudyiwenyama L; Mutoti K; Aineplan N; Gardarsdottir H; Mantel-Teeuwisse AK; Nuebling CM
    BMC Health Serv Res; 2021 Nov; 21(1):1258. PubMed ID: 34801022
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Regulation of medical diagnostics and medical devices in the East African community partner states.
    Rugera SP; McNerney R; Poon AK; Akimana G; Mariki RF; Kajumbula H; Kamau E; Mpawenimana S; Said SY; Toroitich A; Ronoh W; Sollis KA; Sonoiya S; Peeling RW
    BMC Health Serv Res; 2014 Oct; 14():524. PubMed ID: 25366990
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Strengthening regulatory capacity for gene drives in Africa: leveraging NEPAD's experience in establishing regulatory systems for medicines and GM crops in Africa.
    Glover B; Akinbo O; Savadogo M; Timpo S; Lemgo G; Sinebo W; Akile S; Obukosia S; Ouedraogo J; Ndomondo-Sigonda M; Koch M; Makinde D; Ambali A
    BMC Proc; 2018; 12(Suppl 8):11. PubMed ID: 30079102
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of the Performance of the Gulf Cooperation Council Centralised Regulatory Review Process: Strategies to Improve Product Authorisation Efficiency and Quality.
    Hashan HM; Al-Muteb SK; Alismail IA; Alsaleh ON; Alkherb ZM; McAuslane N; Walker SR
    Pharmaceut Med; 2022 Aug; 36(4):223-231. PubMed ID: 35767216
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Advancing African Medicines Agency through Global Health Diplomacy for an Equitable Pan-African Universal Health Coverage: A Scoping Review.
    Chattu VK; Dave VB; Reddy KS; Singh B; Sahiledengle B; Heyi DZ; Nattey C; Atlaw D; Jackson K; El-Khatib Z; Eltom AA
    Int J Environ Res Public Health; 2021 Nov; 18(22):. PubMed ID: 34831511
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.